Cargando…
Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass
PURPOSE : Intestinal remodeling and adaptation of the alimentary limb after Roux-en-Y gastric bypass (RYGB) play an important role in the pathophysiological events that lead to type 2 diabetes mellitus (T2DM) improvement. Intestinal absorptive loop hypertrophy and growth following surgery have been...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671997/ https://www.ncbi.nlm.nih.gov/pubmed/36301409 http://dx.doi.org/10.1007/s11695-022-06328-x |
_version_ | 1784832662212444160 |
---|---|
author | Pérez-Arana, Gonzalo-Martín Díaz-Gómez, Alfredo Camacho-Ramírez, Alonso Ribelles-García, Antonio Almorza-Gomar, David Gracia-Romero, Manuel Prada-Oliveira, José-Arturo |
author_facet | Pérez-Arana, Gonzalo-Martín Díaz-Gómez, Alfredo Camacho-Ramírez, Alonso Ribelles-García, Antonio Almorza-Gomar, David Gracia-Romero, Manuel Prada-Oliveira, José-Arturo |
author_sort | Pérez-Arana, Gonzalo-Martín |
collection | PubMed |
description | PURPOSE : Intestinal remodeling and adaptation of the alimentary limb after Roux-en-Y gastric bypass (RYGB) play an important role in the pathophysiological events that lead to type 2 diabetes mellitus (T2DM) improvement. Intestinal absorptive loop hypertrophy and growth following surgery have been related to GLP-2 secretion by ileal L-cells. The secretion of peptide tyrosine-tyrosine (PYY) enterohormone after a meal has been proposed as a trigger for ileal secretion of GLP-1. Our aim is to determine the role of PYY as a GLP-2 secretion modulator as an adaptation result in the alimentary limb after RYGB. METHOD: We used a non-obese euglycemic rodent model. Circulating glucose, insulin, PYY, and GLP-2 were measured in the experimental and control groups. We used four groups: fasting control, Sham-operated, RYGB-operated (RYGB), and RYGB-operated and treated with BIIE0246 (RYGB + BII). BIIE0246 is a NPY2 receptor antagonist in L-cells. Intestinal glucose transporters and GLP-1 and PYY gut expression and hypertrophy were analyzed after 12 weeks of surgery. RESULTS: RYGB increased PYY3-36 plasma levels in rats with or without BII treatment. A high-insulin response was observed in the RYGB group but not in the control or RYGB + BII groups. BIIE0246 treatment limited plasma GLP-2 levels. In the alimentary intestinal limb, hypertrophy and SGLT1 and GLUT1 expression appeared to be reduced after RYGB compared to controls. CONCLUSION: The postprandial ileal PYY secretion is enhanced after RYGB. This increase mediates GLP-2 release through its binding to the Y2 receptor on L-cells. This mechanism plays a role in alimentary limb hypertrophy after surgery. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-9671997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-96719972022-11-19 Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass Pérez-Arana, Gonzalo-Martín Díaz-Gómez, Alfredo Camacho-Ramírez, Alonso Ribelles-García, Antonio Almorza-Gomar, David Gracia-Romero, Manuel Prada-Oliveira, José-Arturo Obes Surg Original Contributions PURPOSE : Intestinal remodeling and adaptation of the alimentary limb after Roux-en-Y gastric bypass (RYGB) play an important role in the pathophysiological events that lead to type 2 diabetes mellitus (T2DM) improvement. Intestinal absorptive loop hypertrophy and growth following surgery have been related to GLP-2 secretion by ileal L-cells. The secretion of peptide tyrosine-tyrosine (PYY) enterohormone after a meal has been proposed as a trigger for ileal secretion of GLP-1. Our aim is to determine the role of PYY as a GLP-2 secretion modulator as an adaptation result in the alimentary limb after RYGB. METHOD: We used a non-obese euglycemic rodent model. Circulating glucose, insulin, PYY, and GLP-2 were measured in the experimental and control groups. We used four groups: fasting control, Sham-operated, RYGB-operated (RYGB), and RYGB-operated and treated with BIIE0246 (RYGB + BII). BIIE0246 is a NPY2 receptor antagonist in L-cells. Intestinal glucose transporters and GLP-1 and PYY gut expression and hypertrophy were analyzed after 12 weeks of surgery. RESULTS: RYGB increased PYY3-36 plasma levels in rats with or without BII treatment. A high-insulin response was observed in the RYGB group but not in the control or RYGB + BII groups. BIIE0246 treatment limited plasma GLP-2 levels. In the alimentary intestinal limb, hypertrophy and SGLT1 and GLUT1 expression appeared to be reduced after RYGB compared to controls. CONCLUSION: The postprandial ileal PYY secretion is enhanced after RYGB. This increase mediates GLP-2 release through its binding to the Y2 receptor on L-cells. This mechanism plays a role in alimentary limb hypertrophy after surgery. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2022-10-27 2022 /pmc/articles/PMC9671997/ /pubmed/36301409 http://dx.doi.org/10.1007/s11695-022-06328-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Contributions Pérez-Arana, Gonzalo-Martín Díaz-Gómez, Alfredo Camacho-Ramírez, Alonso Ribelles-García, Antonio Almorza-Gomar, David Gracia-Romero, Manuel Prada-Oliveira, José-Arturo Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass |
title | Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass |
title_full | Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass |
title_fullStr | Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass |
title_full_unstemmed | Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass |
title_short | Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass |
title_sort | peptide tyrosine-tyrosine triggers glp-2-mediated intestinal hypertrophy after roux-en-y gastric bypass |
topic | Original Contributions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671997/ https://www.ncbi.nlm.nih.gov/pubmed/36301409 http://dx.doi.org/10.1007/s11695-022-06328-x |
work_keys_str_mv | AT perezaranagonzalomartin peptidetyrosinetyrosinetriggersglp2mediatedintestinalhypertrophyafterrouxenygastricbypass AT diazgomezalfredo peptidetyrosinetyrosinetriggersglp2mediatedintestinalhypertrophyafterrouxenygastricbypass AT camachoramirezalonso peptidetyrosinetyrosinetriggersglp2mediatedintestinalhypertrophyafterrouxenygastricbypass AT ribellesgarciaantonio peptidetyrosinetyrosinetriggersglp2mediatedintestinalhypertrophyafterrouxenygastricbypass AT almorzagomardavid peptidetyrosinetyrosinetriggersglp2mediatedintestinalhypertrophyafterrouxenygastricbypass AT graciaromeromanuel peptidetyrosinetyrosinetriggersglp2mediatedintestinalhypertrophyafterrouxenygastricbypass AT pradaoliveirajosearturo peptidetyrosinetyrosinetriggersglp2mediatedintestinalhypertrophyafterrouxenygastricbypass |